



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

Contents lists available at ScienceDirect

Virology

journal homepage: www.elsevier.com/locate/yviro

Review

Innate immune restriction and antagonism of viral RNA lacking 2'-O methylation

Jennifer L. Hyde^a, Michael S. Diamond^{a,b,c,d,*}^a Departments of Medicine, Washington University School of Medicine, St Louis., MO 63110, USA^b Molecular Microbiology, Washington University School of Medicine, St Louis., MO 63110 USA^c Pathology & Immunology, Washington University School of Medicine, St Louis., MO 63110, USA^d The Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis., MO 63110, USA

ARTICLE INFO

Article history:

Received 1 December 2014

Accepted 22 January 2015

Available online 11 February 2015

Keywords:

Interferon

Viral pathogenesis

RNA structure

Methylation

Innate immunity

Immune evasion

ABSTRACT

N-7 and 2'-O methylation of host cell mRNA occurs in the nucleus and results in the generation of cap structures (cap 0, m⁷GpppN; cap 1, m⁷GpppNm) that control gene expression by modulating nuclear export, splicing, turnover, and protein synthesis. Remarkably, RNA cap modification also contributes to mammalian cell host defense as viral RNA lacking 2'-O methylation is sensed and inhibited by IFIT1, an interferon (IFN) stimulated gene (ISG). Accordingly, pathogenic viruses that replicate in the cytoplasm have evolved mechanisms to circumvent IFIT1 restriction and facilitate infection of mammalian cells. These include: (a) generating cap 1 structures on their RNA through cap-snatching or virally-encoded 2'-O methyltransferases, (b) using cap-independent means of translation, or (c) using RNA secondary structural motifs to antagonize IFIT1 binding. This review will discuss new insights as to how specific modifications at the 5'-end of viral RNA modulate host pathogen recognition responses to promote infection and disease.

© 2015 Elsevier Inc. All rights reserved.

Contents

Eukaryotic N-7- and 2'-O- methylation of host mRNA	67
2'-O-methylation and host-mediated restriction of viral RNA	68
Mechanisms of viral evasion of Ifit1-mediated restriction	71
Viral 2'-O MTases	71
Cap-snatching by viruses	71
Cap-independent translation	71
RNA structure-mediated antagonism	72
Conclusions	72
Acknowledgments	72
References	72

Pathogen associated molecular patterns (PAMPs) that are unique to viral RNA (e.g., double-stranded RNA or 5'-ppp-RNA) are recognized by Toll-like receptors (TLR3, TLR7, and TLR8) and the RIG-I-like receptors (RLR: RIG-I and MDA-5) in the host cell endosome

and cytoplasm. Upon binding their respective PAMPs these pathogen recognition receptors (PRRs) trigger signaling cascades that induce nuclear translocation of transcription factors (IRF-3, IRF-7, and NF-κB), which induce expression of antiviral type I interferons (IFN-α and -β) (reviewed in [Bowie and Unterholzner \(2008\)](#)). IFN-α and -β bind to and signal through the type I IFN receptor (IFNAR) in an autocrine and paracrine manner to induce the expression of hundreds of IFN-stimulated genes (ISGs) that have diverse antiviral and immune regulatory functions. Recent studies have identified an

* Correspondence to: Departments of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8051, St Louis, Missouri 63110, USA. Tel.: +1 314 362 2842; fax: +1 314 362 9230.

E-mail address: diamond@borcim.wustl.edu (M.S. Diamond).




Fig. 1. Overview of cap 1 structure formation in eukaryotic and viral systems. (A) Chemical structure of the G-cap and methylation sites which form cap 0, cap 1, and cap 2 structures. (B) The eukaryotic canonical capping pathway. Newly transcribed RNA (pppNp-RNA) is cleaved by RNA triphosphatase at the γ -phosphate to yield diphosphate RNA (ppNp-RNA). Guanylyltransferase, which forms part of the bifunctional capping enzyme (hCAP) that also encodes triphosphatase activity, then hydrolyzes the α -phosphate from GTP and transfers the GMP moiety to the ppNp-RNA acceptor to generate GpppNp. GpppNp-RNA is methylated by the *N*-7 MTase, which transfers a methyl group from an *S*-adenosyl-L-methionine (AdoMet) donor to the unmethylated G-cap acceptor, producing cap 0 RNA (m⁷GpppNp) and *S*-adenosyl-L-homocysteine (AdoHcy) as a by-product. The 2'-*O*-ribose MTase (hMTTr1) then transfers a methyl group from the AdoMet donor to the first and second nucleotides of cap 0 RNA to generate cap 1 and cap 2 structures, respectively. (C) Generation of viral cap 1 structures through non-canonical capping and methylation pathways. Analogous to eukaryotic RNA methylation, some viruses (e.g. coronavirus and poxvirus) catalyze cap 0 and cap 1 formation separately via two distinct enzymes or enzymes complexes (left). In contrast, other viruses (e.g. flavivirus and reovirus) catalyze *N*-7 and 2'-*O* methylation sequentially via a single enzyme (right). Although the cap 1 end product is identical between host and viral transcripts structural differences in the viral and eukaryotic enzymes that catalyze these reactions and their distinct modes of ligand binding make viral 2'-*O* MTases potential targets for inhibitor design.

additional PAMP on some viral mRNA lacking-2'-*O* methylation, which is recognized by the ISG Ifit1 (Habjan et al., 2013; Hyde et al., 2014; Kimura et al., 2013; Menachery et al., 2014; Szretter et al., 2012). As mRNA of higher eukaryotic organisms contain 2'-*O* methylation on their 5' cap structures, Ifit1 may have evolved, in part, to distinguish self from non-self RNA.

Eukaryotic *N*-7- and 2'-*O*- methylation of host mRNA

RNA methylation is a common post-transcriptional modification that regulates gene expression by influencing diverse aspects of RNA biology including nuclear export, splicing, transcript stability, and translation. In eukaryotic cells, host mRNAs are capped at the 5' end by an inverted *N*-7 methyl guanosine nucleoside (m⁷GpppN), which is linked to the RNA moiety by a triphosphate bridge (Fig. 1A). The presence of the m⁷G cap (cap 0) structure enhances mRNA translation by promoting the association of translation initiation factors such as eIF4E with the 5' end, as transcripts lacking methylated 5' caps fail to complex efficiently with 40S ribosomal subunits (Both et al., 1975; Gebauer and Hentze, 2004; Shatkin, 1985). Additionally,

methylated 5' cap structures stabilize RNA transcripts by preventing degradation by 5'-3' cellular exonucleases (reviewed in (Garneau et al., 2007)), and regulate early steps in RNA transcription by associating with gene promoters (reviewed in (Bentley, 2005; Pei et al., 2003; Schroeder et al., 2000)).

Addition of the m⁷G cap occurs co-transcriptionally in the nucleus via a three-step enzymatic reaction (Fig. 1B). Newly transcribed RNA (pppNp-RNA) is cleaved by RNA triphosphatase at the γ -phosphate to yield diphosphate RNA (ppNp-RNA) (Yagi et al., 1983). Guanylyltransferase, which forms part of the bifunctional capping enzyme (hCAP) that also encodes triphosphatase activity, then hydrolyzes the α -phosphate from GTP and transfers the GMP moiety to the ppNp-RNA acceptor to generate GpppNp (Venkatesan et al., 1980; Venkatesan and Moss, 1980; Yagi et al., 1983; Yamada-Okabe et al., 1998). This reaction shows specificity for ppNp-RNA as pppNp-RNA is capped far less efficiently, and pNp-RNA not at all. GpppNp-RNA is then methylated by a distinct enzyme, (guanine-*N*-7-)methyltransferase (*N*-7 MTase), which modifies the 5' terminal guanosine of dinucleoside and polynucleoside triphosphate moieties (Ensinger and Moss, 1976). In this reaction the *N*-7 MTase transfers a methyl group from an *S*-adenosyl-L-methionine (AdoMet) donor to the

unmethylated G-cap acceptor, producing cap 0 RNA (m⁷GpppNp) and S-adenosyl-L-homocysteine (AdoHcy) as a by-product.

Whereas N-7-methylation is conserved among all eukaryotes, 2'-O-ribose methylation of the first or the first and second transcribed nucleotides immediately downstream of the m⁷G cap (which forms cap 1 and cap 2 structures, respectively) is present only in mRNA of bony fish and higher eukaryotes (Varela et al., 2014). The additional 2'-O methylation event and generation of cap 1 structures facilitates splicing of small nuclear RNAs (snRNA) (Donmez et al., 2004) and enhances translation of mRNA during oocyte maturation (Kuge et al., 1998; Kuge and Richter, 1995). Beyond these functions, 2'-O methylation and cap 1 structures contribute to the recognition and restriction of non-self RNA, particularly in the context of the cell-intrinsic immune response to viruses (Daffis et al., 2010; Habjan et al., 2013; Hyde et al., 2014; Kimura et al., 2013). Indeed, expression of the MTase (hMTTr1, also known as ISG95) that catalyzes formation of cap 1 structures is augmented by interferon (IFN), supporting a role for differential methylation of RNA cap structures in immune detection and restriction (Haline-Vaz et al., 2008).

2'-O-ribose methylation of host cell mRNA occurs co-transcriptionally in the nucleus through the actions of hMTTr1 (Belanger et al., 2010; Pei et al., 2003; Schroeder et al., 2000). Analogous to the nuclear N-7 MTase, hMTTr1 associates with Pol II (Haline-Vaz et al., 2008) and can methylate both m⁷GpppG and GpppG RNA *in vitro* (Belanger et al., 2010; Langberg and Moss, 1981; Smietanski et al., 2014). The crystal structure of the human 2'-O-MTase catalytic domain complex (Smietanski et al., 2014) has revealed that recognition of the guanosine cap by eukaryotic and viral 2'-O-MTases occurs in a distinct manner (Egloff et al., 2002, 2007; Hodel et al., 1998). Proposed differences in the structural interaction of host and viral 2'-O-MTases with their RNA ligands has been used as the basis for development of targeted viral MTase inhibitors, as discussed below.

2'-O-methylation and host-mediated restriction of viral RNA

2'-O methylation of cap structures contributes to the sensing of non-self RNA and restriction of viral replication and pathogenesis. Ifit1, an IFN-induced RNA-binding protein, mediates this effect by preferentially binding to viral RNAs lacking 2'-O-methylation at their 5' end and inhibiting RNA translation (Daffis et al., 2010; Kimura et al., 2013; Kumar et al., 2014; Li et al., 2013; Menachery et al., 2014;

Szretter et al., 2012; Zhang et al., 2014; Zust et al., 2011, 2013). Introduction of loss-of-function point mutations into the catalytic tetrad (KDKE) of flavivirus, coronavirus, and poxvirus 2'-O-MTases (e.g., West Nile virus NS5-E218A, Japanese encephalitis virus NS5-E218A, Dengue virus NS5-E216A and E217A, mouse hepatitis virus NSP16 D130A, human coronavirus 229E NSP16-D129A, SARS-coronavirus NSP16-D130A, and vaccinia virus J3-K175R) resulted in attenuated virus infections both *in vitro* and *in vivo* (Daffis et al., 2010; Kimura et al., 2013; Kumar et al., 2014; Li et al., 2013; Menachery et al., 2014; Szretter et al., 2012; Zhang et al., 2014; Zust et al., 2011, 2013). Mutations that abrogated 2'-O methylation were associated with decreased viral replication in wild-type mice and cells, and an increased sensitivity to the antiviral actions of type I IFN. Replication and virulence was restored in the absence of an intact IFN signaling response or Ifit1 (Daffis et al., 2010; Szretter et al., 2012; Zust et al., 2011) in primary cell culture (dendritic cells, macrophages, and neurons) or *in vivo*. Attenuated 2'-O-MTase mutant viruses have potential as vaccines as they retain immunogenicity and confer protection against challenge with pathogenic flaviviruses, rhabdoviruses, and coronaviruses (Li et al., 2013; Ma et al., 2014; Menachery et al., 2014; Zhang et al., 2014; Zust et al., 2013).

Ifit1 belongs to a family of IFN-induced proteins (human IFIT1 and IFIT1B, IFIT2, IFIT3, and IFIT5; mouse Ifit1, Ifit1b, Ifit1c, Ifit2, and Ifit3) that are induced rapidly and expressed to high levels in an IFN-dependent and -independent manner following virus infection (Guo et al., 2000b; Kitamura et al., 2001; Sharma et al., 2003; Smith and Herschman, 1996; Terenzi et al., 2005). IFIT genes exhibit low sequence identity between both orthologs and paralogs (31% to 69%) but are related by their multiple tetratricopeptide repeat (TPR) domains (Smith and Herschman, 1996). The TPR motif comprises a degenerate 34 amino-acid sequence containing eight loosely conserved hydrophobic residues, and is important in mediating protein-protein interactions (Goebel and Yanagida, 1991; King et al., 1995; Lamb et al., 1995; Terlecky et al., 1995; Tzamaras and Struhl, 1995). TPR motifs form an amphipathic antiparallel helix and higher order helical structures, although the overall structure may vary considerably among proteins (reviewed in D'Andrea and Regan (2003)).

The crystal structures of the N-terminus of human IFIT1, the full-length IFIT2 homodimer, and full-length IFIT5 monomer have helped to elucidate how IFIT proteins interact with RNA ligands (Abbas et al., 2013; Feng et al., 2013; Katibah et al., 2013; Yang et al., 2012).

Table 1
Summary of Ifit-ligand binding.

	5'-OH	5'-ppp	Cap (GpppNp)	Cap 0 (7mGpppNp)	Cap 1 (7mGpppNm)	References
Human IFIT1	-	- (> 1.4 μM) +(242 nM)	+	+(23 ± 4 nM)	-	Habjan et al. (2013), Pichlmair et al., (2011), Kumar et al. (2014) and Abbas et al. (2013)
Human IFIT1B				+	+	Kumar et al. (2014)
Mouse Ifit1	-	-	+	+	-	Habjan et al., (2013), Kimura et al. (2013) and Pichlmair et al. (2011)
Mouse Ifit1c		+			-	Habjan et al. (2013)
Rabbit IFIT1			+	+(20 ± 1 nM)	-	Kumar et al. (2014)
Rabbit IFIT1B		- (> 1.4 μM)		+(9 ± 2 nM)	+(457 ± 24 nM)	Kumar et al. (2014)
Human IFIT2	-	-	-	-	-	Habjan et al. (2013), Kumar et al. (2014), Pichlmair et al. (2011) and Yang et al. (2012)
Mouse Ifit2	+	+(dsRNA)	-		-	Habjan et al. (2013)
Human IFIT3	-	-	-	-	-	Abbas et al., (2013), Habjan et al., 2013, Kumar et al., 2014 and Pichlmair et al. (2011)
Mouse Ifit3			-		-	Habjan et al. (2013)
Human IFIT5	-	+(372 ± 21 nM) (1.4 ± 0.18 μM)	-	-	-	Abbas et al. (2013), Feng et al. (2013), Habjan et al. (2013), Katibah et al. (2014) and Kumar et al. (2014)

No or minimal binding (-), positive binding (+). Dissociation constant (K_D) is indicated in parentheses. Unavailable data is indicated by gray cells. Specificity for dsRNA binding is indicated (dsRNA).

Although a complete structure of mouse or human Ifit1 has not been determined, the sequence and structural homology between the N-terminal subdomains of IFIT1 and IFIT5 suggest a conserved mode of RNA ligand binding (Abbas et al., 2013). IFIT1, IFIT2, and IFIT5 all form superhelical structures containing a highly positively charged groove or pocket, which accommodates binding of different RNA ligands. Although the precise mode and specificity of RNA binding differs among IFIT proteins (Table 1), mutation of positively charged residues lying within this pocket is sufficient to abrogate RNA binding (Abbas et al., 2013; Katibah et al., 2013; Kumar et al., 2014; Pichlmair et al., 2011). IFIT1 may also undergo conformational changes upon ligand binding, as has been observed for IFIT5 (Abbas et al., 2013; Katibah et al., 2014). Unbound IFIT5 adopts a relatively open conformation near the binding pocket, presumably to facilitate interaction with different RNA ligands; upon association with RNA, structural changes result in a more closed conformation (Katibah et al., 2014).

Biochemical analysis also has contributed to our understanding of the specificity and dynamics of Ifit1-RNA binding (Table 1). Initial studies indicated that IFIT1 interacted with RNA transcripts containing 5'-ppp moieties (Pichlmair et al., 2011) in a manner similar to IFIT5 (Abbas et al., 2013; Feng et al., 2013; Katibah et al., 2013;

Pichlmair et al., 2011). Surface plasmon resonance, filter binding, primer extension inhibition, and electromobility shift assays, all have defined a low affinity ($K_D \sim 250$ nM to > 1 μ M) interaction between IFIT1 and 5'-ppp RNA (Kumar et al., 2014; Pichlmair et al., 2011), with one study indicating this strength of binding was sufficient to sequester negative strand RNA and inhibit infection of influenza A, vesicular stomatitis, and Rift Valley fever viruses (Pichlmair et al., 2011). IFIT1/Ifit1 binds more avidly ($K_D \sim 9$ to 30 nM) to viral or host cap 0 RNA lacking 2'-O methylation in a sequence-independent manner (Habjan et al., 2013; Hyde et al., 2014; Kimura et al., 2013; Kumar et al., 2014). The binding of cap 0 RNA by IFIT1 appears unique as IFIT2/Ifit2, IFIT3/Ifit3, and IFIT5 fail to bind with appreciable affinity (Habjan et al., 2013; Kumar et al., 2014). Although N-7-methylation of RNA (m^7 GpppNp-RNA) was not required for IFIT1 binding, this modification enhanced binding to IFIT1 and IFIT1B compared to unmethylated G-capped RNA (GpppNp-RNA). Nucleotides proximal to the methylated cap 0 and triphosphate bridge likely modulate IFIT1-RNA interactions, as primer extension assays suggest that at least ~ 4 or 5 nucleotides downstream of the cap 0 structure are bound by IFIT1 (Kumar et al., 2014). Analogously, nucleotides proximal to cap structures also




Fig. 2. Ifit1 inhibits diverse aspects of RNA translation. Canonical cap-dependent translation proceeds as follows: (1) the 40S ribosomal subunit complexes with eIF3 and the ternary complex (eIF2-GTP-Met-tRNA) to form the 43S pre-initiation complex. (2) eIF4E associates with the cap and recruits the eIF4F cap-binding complex (eIF4A, eIF4E, eIF4G). (3) eIF4F facilitates unwinding of the RNA and the 43S pre-initiation complex is recruited to form the 48S complex. (4) The 48S complex scans along the mRNA for the AUG initiator codon. (5) The 60S ribosomal subunit is recruited to the 48S complex to form the 80S initiator complex, which translates the mRNA. Ifit1/IFIT1 binds to subunits of the eIF3 complex (a) to prevent ternary complex formation or 43S formation and recruitment (Guo et al., 2000a; Hui et al., 2003, 2005; Kumar et al., 2014; Wang et al., 2003). (b) IFIT1 interaction with the 40S ribosomal subunit abrogates 48S formation (Kumar et al., 2014). (c) Ifit1/IFIT1 directly associates with cap 0 viral RNA and inhibits recruitment of eIF4E and eIF4F to RNA.

enhance binding of other cap-binding proteins to RNA (Chung et al., 1994; Kumar et al., 2014). This concept is supported by recent studies demonstrating that RNA secondary structure can inhibit Ifit1 binding independent of cap methylation status (Hyde et al., 2014), possibly through steric hindrance of Ifit1-RNA interactions. The influence of *N*-7-methylation status of cap 0 structures on IFIT1 binding may be species-specific, as differences in ligand binding affinities were observed for rabbit IFIT1 (Kumar et al., 2014).

Varying ligand specificities of human IFIT1 and IFIT1B suggests overlapping yet distinct biological functions of IFIT1-like genes. In contrast to IFIT1, which binds cap 0 but not cap 1 RNA, the paralog IFIT1B binds both cap 0 and cap 1 structures (Kumar et al., 2014). This cap 1 binding activity has fostered the hypothesis that IFIT1B has additional translational control functions in the absence of an antiviral response. This is supported indirectly by the observations that IFIT1B expression is not induced by IFN or PAMP stimulation (Fensterl and Sen, 2011; Liu et al., 2013), and can bind non-viral RNA ligands (Kumar et al., 2014).

Although IFIT1 has been implicated as an IFN-induced protein that inhibits translation of viral mRNA, the precise mechanism has remained unclear (Andrejeva et al., 2013; Guo et al., 2000a; Habjan et al., 2013; Hui et al., 2003, 2005; Kimura et al., 2013; Kumar et al., 2014; Wang et al., 2003). In canonical cap-dependent translation (Fig. 2) (reviewed in Jackson et al. (2010)), the 40S ribosomal subunit complexes with eIF3 and the ternary complex (eIF2-GTP-Met-tRNA) to form the 43S pre-initiation complex. This pre-

initiation complex is recruited to mRNA via cap-binding complex eIF4F (eIF4A, eIF4E, eIF4G), which together forms the 48S complex and scans mRNA sequences for the AUG initiator codon. Earlier studies suggested that Ifit1 and IFIT1 bind to subunits of the eIF3 complex to prevent downstream events required for translation initiation (Guo et al., 2000a; Hui et al., 2003, 2005; Wang et al., 2003). The interaction of IFIT1 with components of the eIF3 complex is species-specific, as human IFIT1 targets eIF3e, which inhibits association with the ternary complex (Hui et al., 2003). More recently, IFIT1 has been suggested to inhibit translation at the step of 48S complex formation via interaction with the 40S subunit (Kumar et al., 2014). In comparison, mouse Ifit1 reportedly interacts with eIF3c to prevent eIF4F-mediated recruitment of the 43S pre-initiation complex to RNA (Hui et al., 2005).

Ifit1 and IFIT1 initially were suggested to associate directly with translation factors in an RNA-independent manner, effectively sequestering them from the active translation pool. However, this mechanism did not explain how IFIT1 preferentially could inhibit viral versus host mRNA translation. Recent studies show that Ifit1 and IFIT1 directly bind cap 0 RNA and prevent recruitment of translation factors (Habjan et al., 2013; Hyde et al., 2014; Kimura et al., 2013; Kumar et al., 2014). Because of its relatively greater affinity for RNA lacking 2'-*O* methylation, IFIT1 can out-compete eIF4E or eIF4F for binding, and thus remove cap 0 RNA from the actively translating pool (Kumar et al., 2014). Additionally, initiator and elongator tRNAs also compete with cap 0 RNA for IFIT1 and




Fig. 3. Viral mechanisms of Ifit1 evasion and antagonism. Viruses generate cap 1 structures through (a) cap-snatching (orthomyxoviruses, bunyaviruses, arenaviruses) whereby cap 1 is cleaved from host mRNA transcripts and used as a primer for viral RNA transcription. In contrast to orthomyxoviruses, which cap-snatch from mRNA in the nucleus, bunyaviruses associate with and sequester cap 1 containing nonsense-mRNA transcripts in cellular P bodies where N protein protects cap 1 from degradation. Some viruses mimic cap 1 structures via virally-encoded 2'-*O* MTases (flaviviruses, coronaviruses, rhabdoviruses, paramyxoviruses, reoviruses, and poxviruses). Other viruses (picornaviruses, caliciviruses, and hepaciviruses) circumvent Ifit1-mediated restriction by using non-canonical cap-like structures (VPg) at their 5' end or IRES-mediated cap-independent translation (b). Alphaviruses antagonize Ifit1 function directly by inhibiting association with viral RNA through the generation of stable secondary structures in the 5'-UTR (c).

IFIT1B binding (Katibah et al., 2013, 2014), suggesting that IFIT1 may inhibit protein synthesis of mRNA independent of cap methylation status, by sequestering tRNAs from the translating pool (Kumar et al., 2014). This study also demonstrated an association of IFIT1 with the 40S ribosomal subunit that was independent of RNA binding, suggesting yet another mechanism of general translation inhibition. The precise mechanism of translation inhibition may be influenced by the potential of IFIT1 to form homo- or heterodimers with other IFIT proteins (Habjan et al., 2013; Pichlmair et al., 2011). Although the functional relevance of IFIT oligomerization requires exploration, it is an attractive hypothesis by which the cell could use IFIT proteins to modulate translation control under different cellular conditions.

Mechanisms of viral evasion of Ifit1-mediated restriction

Viruses have evolved diverse mechanisms to circumvent IFIT1-mediated restriction including: (a) generating cap 1 structures on their RNA by cap-snatching, or using virally- or host-encoded 2'-O MTases; (b) using cap-independent means of translation; or (c) using RNA secondary structural motifs to antagonize Ifit1 binding (Fig. 3).

Viral 2'-O MTases

Many RNA viruses that replicate in the cytoplasm (including Flaviviruses, Coronaviruses, Poxviruses, Paramyxoviruses, Reoviruses, and Rhabdoviruses) encode their own viral 2'-O MTases, which catalyze the formation of cap structures on viral mRNA that mimic those present on host mRNAs. Mutant viruses encoding defective 2'-O MTases are sensitive to Ifit1-mediated restriction and attenuated *in vivo* (Daffis et al., 2010; Li et al., 2013; Menachery et al., 2014; Szretter et al., 2012; Zust et al., 2011). Although cap 1 structures are generated by virus-encoded MTases, the mechanism of cap methylation is distinct compared to eukaryotes (Fig. 1C). Structural and biochemical analysis of the MTases from eukaryotic hosts and viruses have illustrated unique characteristics of viral 2'-O MTases, (Assenberg et al., 2007; Egloff et al., 2002, 2007; Hodel et al., 1998), making them potential targets for drug development (reviewed in Dong et al. (2008) and Ferron et al. (2012)).

In contrast to cap formation in eukaryotic cells and by certain viruses (e.g., Poxviruses and Coronaviruses) where *N*-7 and 2'-O methylation is catalyzed by two enzymes, flaviviruses, reoviruses, and rhabdoviruses catalyze RNA methylation with a single viral enzyme (Assenberg et al., 2007; Bujnicki and Rychlewski, 2001, 2002; Ferron et al., 2002; Hercyk et al., 1988; Ray et al., 2006; Reinisch et al., 2000). The *N*-7 and 2'-O MTase activities of flaviviruses are encoded by the N-terminal domain of the NS5 gene (Ray et al., 2006). The NS5 MTase domain of flaviviruses possesses a Rossmann-like superfold and comprises a catalytic core of a seven-stranded β -sheet flanked by α -helices (reviewed in Martin and McMillan (2002) and Schubert et al. (2003)). The catalytic tetrad (KDKE) of MTases is conserved in the flaviviruses, poxviruses, reoviruses, and coronaviruses (Assenberg et al., 2007; Decroly et al., 2011; Egloff et al., 2002, 2007). Flavivirus MTase shows preferential binding for GTP, m⁷GTP, and m⁷GpppA within the cap-binding pocket. Substrates containing the first two native nucleotides (AG) of the flavivirus genome bind with higher affinity to the MTase than non-native nucleotide substrates, which may account for why these nucleotides are strictly conserved (Cleaves and Dubin, 1979; Egloff et al., 2007). m⁷GpppA and GpppA substrates also bind with different affinities, perhaps due to different modes of interaction of these substrates with the MTase (Egloff et al., 2002).

Reovirus capping and methylation is catalyzed by the λ 2 protein, which forms pentamers that comprises part of the reovirus core (Koonin, 1993; Luongo et al., 1998; Reinisch et al., 2000). λ 2 pentamers form a cylindrical structure through which viral mRNA passes and is

capped and methylated at the *N*-7 and 2'-O position. The spatial arrangement of the catalytic sites within the λ 2 pentamer indicates that capping, *N*-7- and 2'-O-methylation of viral RNA occurs sequentially as it shuttles from one end of the pentamer to the other. The presence of a flap at the terminus of the pentamer has been suggested to retain nascent viral RNA and ensure proper capping and methylation (Reinisch et al., 2000).

The *N*-7 and 2'-O MTase activity of coronaviruses are encoded by the viral NSP14 and NSP16 genes, respectively. While the coronavirus NSP14 *N*-7 MTase modifies nascent viral transcripts in a sequence-independent manner (Chen et al., 2013) the 2'-O MTase is sequence-specific, and requires a second viral protein (NSP10) as a cofactor (Chen et al., 2011; Decroly et al., 2008) for both RNA substrate and AdoMet binding.

The poxvirus 2'-O MTase VP39 catalyzes the formation of cap 1 structures. In contrast to reovirus λ 2 and coronavirus NSP16, VP39 does not require oligomerization or cofactor binding for function (Hodel et al., 1998, 1996; Shi et al., 1997). Viral RNA binding to VP39 is mediated by a hydrophobic pocket, which together with base stacking, is believed to accommodate substrates in a sequence-independent manner (Hodel et al., 1998, 1996).

Cap-snatching by viruses

Orthomyxoviruses, bunyaviruses, and arenaviruses generate cap 1 structures by removing them from host mRNA transcripts via a mechanism called 'cap-snatching'. During influenza virus infection, cap 1 structures are acquired from host nuclear mRNAs and used to prime viral RNA transcription. Both *N*-7 and 2'-O methylation of the cap are required for efficient transcriptional priming of influenza (Bouloy et al., 1980), which is mediated via PB2, the cap-binding protein of the influenza polymerase complex (PB1-PB2-PA) (Honda et al., 1999). Following cap 1 binding the viral polymerase complex cleaves the donor transcript 10 to 14 nucleotides downstream of the cap 1 structure (Dias et al., 2009; Li et al., 2001; Plotch et al., 1979, 1981; Shi et al., 1995; Yuan et al., 2009). The polymerase complex preferentially cleaves at purine residues and requires additional sequence specificity, such as A/U at nucleotide positions 9–11, and yields a 3'-OH moiety (Kawakami et al., 1983; Plotch et al., 1981).

Bunyavirus cap-snatching exploits the host eukaryotic nonsense-mediate mRNA decay pathway to generate cap 1 primers for viral transcription (Cheng and Mir, 2012). Bunyavirus nucleocapsid (N) binds preferentially to host cap 1 mRNA with premature stop codons and then sequesters mRNA in processing (P) bodies within the cytoplasm where RNA degradation takes place (Mir et al., 2008). Association with N protects cap 1 from degradation by the host decapping machinery, and results in the generation of cap 1 RNA oligomers of ~180 nucleotides (Hopkins et al., 2013; Mir et al., 2008). The viral RNA-dependent RNA polymerase (L protein) then cleaves cap 1 oligomers at a G residue approximately 14 nucleotides downstream of cap 1 to yield 'mature' cap 1 oligomers that serve as primers for viral RNA transcription (Cheng and Mir, 2012; Jin and Elliott, 1993; Mir et al., 2008, 2010; Patterson et al., 1984).

Less is known about the cap-snatching mechanism used by arenaviruses (Lehmann et al., 2014; Morin et al., 2010; Raju et al., 1990; Reguera et al., 2010). Analogous to bunyaviruses, the arenavirus L protein has RNA-dependent RNA polymerase activity (Lukashevich et al., 1997; Vieth et al., 2004). L protein also encodes endonuclease and RNA-binding activity (Morin et al., 2010; Reguera et al., 2010) and is predicted to facilitate cap-binding and cleavage during cap-snatching through an undefined mechanism.

Cap-independent translation

Unlike eukaryotic mRNA and some viral RNA, which have cap 1 structures and use cap-dependent translation mechanisms, other

viruses have a 5' covalently-linked viral protein, VPg (picornaviruses and caliciviruses) and/or an internal ribosomal entry site (IRES; picornaviruses and hepaciviruses) within the 5'-untranslated region (UTR) to facilitate cap-independent translation. In contrast to canonical cap-mediated translation where 43S pre-initiation complex association with the mRNA cap structure is followed by ribosomal scanning and 48S and 60S association, in IRES-mediated translation, the 43S complex binds directly upstream of the IRES and does not require ribosomal scanning or certain translation initiation factors (eIF1, eIF1A, and eIF4E) (reviewed in Jackson et al. (2010) and Pestova et al. (2001)). Viruses lacking 2'-O methylation on their viral mRNA (e.g., picornaviruses, caliciviruses, and hepaciviruses) may use cap-independent translation mechanisms to overcome Ifit1 restriction. In theory, this might occur in one of two ways: (a) the VPg and/or IRES structures sterically hinder Ifit1 binding or (b) the IRES bypasses the step at which IFIT1 inhibits eIF3-dependent translation.

RNA structure-mediated antagonism

Alphaviruses are RNA viruses that replicate in the cytoplasm, translate via a cap-dependent mechanism, and yet lack a virally encoded 2'-O-methyltransferase or cap-snatching mechanism, and thus should be restricted by IFIT1. Alphaviruses have a defined cap 0 structure on the 5' end of their viral genomic and subgenomic RNA (Hefti et al., 1975; Pettersson et al., 1980). Although previous studies had shown that mutations in the Venezuelan equine encephalitis virus (VEEV) 5'-UTR (G→A at position 3) were attenuating (Kinney et al., 1993, 1989) and resulted in enhanced sensitivity to type I IFN treatment (White et al., 2001), the basis for this was unknown. Analogously, mutations that altered the pathogenicity and IFN-sensitivity of other alphaviruses (e.g., Sindbis and Semliki Forest viruses) also mapped to the 5'-UTR (Klimstra et al., 1999; Kobiler et al., 1999; Kuhn et al., 1992; Logue et al., 2008). A recent study explains these earlier findings as it showed that RNA secondary structure in alphavirus 5'-UTR antagonizes Ifit1 binding and antiviral activity (Hyde et al., 2014). Mutations within the 5'-UTR that affect stable RNA structural elements enabled restriction by or antagonism of Ifit1 *in vitro* and *in vivo* by altering binding of Ifit1 to viral RNA. Although this mechanism has not yet been described for other viruses, stable RNA structures are commonly found within the 5'-UTR of many viruses, which might impact Ifit1 recognition in other viral systems.

Conclusions

In higher eukaryotes, detection of viral RNA is critical for initiating and establishing an antiviral state in cells. Cap 0 structures on viral RNA can act as PAMPs that are sensed and restricted by the IFN-induced gene, IFIT1. In contrast to other RNA sensors (TLRs and RLRs) that induce signaling cascades that lead to the expression of type I IFN and ISGs, Ifit1 appears to function predominantly as an antiviral effector molecule. The evolution of multiple mechanisms of antagonism by different families of RNA and DNA viruses indicates the importance of Ifit1 as a key RNA sensor and antiviral molecule. Pathogenic viruses have evolved ways to produce mRNA with 5'-ends that mimic host cellular mRNAs, including viral RNA with N-7 and 2'-O methylation through several independent strategies (encoding capping machinery, 'cap-snatching', or using host capping machinery) or bypassing cap-dependent translation to use other modalities (IRES-dependent) for protein synthesis. The finding that different IFIT proteins exhibit varying affinities for distinct RNA ligands suggests that IFIT genes may recognize additional viral PAMPs, which have yet to be identified. The identification of Ifit1 as a key RNA sensor and antiviral effector and the importance of cap 1 structures in abrogating Ifit1-mediated restriction has provided a

rationale for the development of novel antiviral interventions, including live attenuated vaccines (with 2'-O-methylation or RNA structure mutants) and small molecule inhibitors of viral 2'-O MTases.

Acknowledgments

NIH grants U19 AI083019, U19 AI106772, R01 AI104972, and R01 AI104002 supported this work.

References

- Abbas, Y.M., Pichlmair, A., Gorna, M.W., Superti-Furga, G., Nagar, B., 2013. Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins. *Nature* 494, 60–64.
- Andrejeva, J., Norsted, H., Habjan, M., Thiel, V., Goodbourn, S., Randall, R.E., 2013. ISG56/IFIT1 is primarily responsible for interferon-induced changes to patterns of parainfluenza virus type 5 transcription and protein synthesis. *J. Gen. Virol.* 94, 59–68.
- Assenberg, R., Ren, J., Verma, A., Walter, T.S., Alderton, D., Hurrelbrink, R.J., Fuller, S.D., Bressanelli, S., Owens, R.J., Stuart, D.I., Grimes, J.M., 2007. Crystal structure of the Murray Valley encephalitis virus NS5 methyltransferase domain in complex with cap analogues. *J. Gen. Virol.* 88, 2228–2236.
- Belanger, F., Stepinski, J., Darzynkiewicz, E., Pelletier, J., 2010. Characterization of hMTr1, a human Cap1 2'-O-ribose methyltransferase. *J. Biol. Chem.* 285, 33037–33044.
- Bentley, D.L., 2005. Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. *Curr. Opin. Cell Biol.* 17, 251–256.
- Both, G.W., Furuichi, Y., Muthukrishnan, S., Shatkin, A.J., 1975. Ribosome binding to reovirus mRNA in protein synthesis requires 5' terminal 7-methylguanosine. *Cell* 6, 185–195.
- Bouloy, M., Plotch, S.J., Krug, R.M., 1980. Both the 7-methyl and the 2'-O-methyl groups in the cap of mRNA strongly influence its ability to act as primer for influenza virus RNA transcription. *Proc. Natl. Acad. Sci. USA* 77, 3952–3956.
- Bowie, A.G., Unterholzner, L., 2008. Viral evasion and subversion of pattern-recognition receptor signalling. *Nat. Rev. Immunol.* 8, 911–922.
- Bujnicki, J.M., Rychlewski, L., 2001. Reassignment of specificities of two cap methyltransferase domains in the reovirus lambda 2 protein (RESEARCH0038). *Genome Biol.* 2 0038–0038.6.
- Bujnicki, J.M., Rychlewski, L., 2002. In silico identification, structure prediction and phylogenetic analysis of the 2'-O-ribose (cap 1) methyltransferase domain in the large structural protein of ssRNA negative-strand viruses. *Protein Eng.* 15, 101–108.
- Chen, Y., Su, C., Ke, M., Jin, X., Xu, L., Zhang, Z., Wu, A., Sun, Y., Yang, Z., Tien, P., Ahola, T., Liang, Y., Liu, X., Guo, D., 2011. Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex. *PLoS Pathog.* 7, e1002294.
- Chen, Y., Tao, J., Sun, Y., Wu, A., Su, C., Gao, G., Cai, H., Qiu, S., Wu, Y., Ahola, T., Guo, D., 2013. Structure-function analysis of severe acute respiratory syndrome coronavirus RNA cap guanine-N7-methyltransferase. *J. Virol.* 87, 6296–6305.
- Cheng, E., Mir, M.A., 2012. Signatures of host mRNA 5' terminus for efficient hantavirus cap snatching. *J. Virol.* 86, 10173–10185.
- Chung, T.D., Cianci, C., Hagen, M., Terry, B., Matthews, J.T., Krystal, M., Colonno, R.J., 1994. Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. *Proc. Natl. Acad. Sci. USA* 91, 2372–2376.
- Cleaves, G.R., Dubin, D.T., 1979. Methylation status of intracellular dengue type 2 40S RNA. *Virology* 96, 159–165.
- D'Andrea, L.D., Regan, L., 2003. TPR proteins: the versatile helix. *Trends Biochem. Sci.* 28, 655–662.
- Daffis, S., Sretter, K.J., Schriewer, J., Li, J., Youn, S., Errett, J., Lin, T.Y., Schneller, S., Züst, R., Dong, H., Thiel, V., Sen, G.C., Fensterl, V., Klimstra, W.B., Pierson, T.C., Buller, R.M., Gale Jr., M., Shi, P.Y., Diamond, M.S., 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. *Nature* 468, 452–456.
- Decroly, E., Debarnot, C., Ferron, F., Bouvet, M., Coutard, B., Imbert, I., Gluais, L., Papageorgiou, N., Sharff, A., Bricogne, G., Ortiz-Lombardia, M., Lescar, J., Canard, B., 2011. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex. *PLoS Pathog.* 7, e1002059.
- Decroly, E., Imbert, I., Coutard, B., Bouvet, M., Selisko, B., Alvarez, K., Gorbalenya, A. E., Snijder, E.J., Canard, B., 2008. Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'-O)-methyltransferase activity. *J. Virol.* 82, 8071–8084.
- Dias, A., Bouvier, D., Crepin, T., McCarthy, A.A., Hart, D.J., Baudin, F., Cusack, S., Ruigrok, R.W., 2009. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. *Nature* 458, 914–918.
- Dong, H., Zhang, B., Shi, P.Y., 2008. Flavivirus methyltransferase: a novel antiviral target. *Antivir. Res.* 80, 1–10.
- Donmez, G., Hartmuth, K., Luhrmann, R., 2004. Modified nucleotides at the 5' end of human U2 snRNA are required for spliceosomal E-complex formation. *RNA* 10, 1925–1933.

- Egloff, M.P., Benarroch, D., Selisko, B., Romette, J.L., Canard, B., 2002. An RNA cap (nucleoside-2'-O)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. *EMBO J.* 21, 2757–2768.
- Egloff, M.P., Decroly, E., Malet, H., Selisko, B., Benarroch, D., Ferron, F., Canard, B., 2007. Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. *J. Mol. Biol.* 372, 723–736.
- Ensinger, M.J., Moss, B., 1976. Modification of the 5' terminus of mRNA by an RNA (guanine-7-)-methyltransferase from HeLa cells. *J. Biol. Chem.* 251, 5283–5291.
- Feng, F., Yuan, L., Wang, Y.E., Crowley, C., Lv, Z., Li, J., Liu, Y., Cheng, G., Zeng, S., Liang, H., 2013. Crystal structure and nucleotide selectivity of human IFIT5/ISG58. *Cell Res.* 23, 1055–1058.
- Fensterl, V., Sen, G.C., 2011. The ISG56/IFIT1 gene family. *J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res.* 31, 71–78.
- Ferron, F., Decroly, E., Selisko, B., Canard, B., 2012. The viral RNA capping machinery as a target for antiviral drugs. *Antivir. Res.* 96, 21–31.
- Ferron, F., Longhi, S., Henrissat, B., Canard, B., 2002. Viral RNA-polymerases – a predicted 2'-O-ribose methyltransferase domain shared by all Mononegavirales. *Trends Biochem. Sci.* 27, 222–224.
- Garneau, N.L., Wilusz, J., Wilusz, C.J., 2007. The highways and byways of mRNA decay. *Nature reviews. Mol. Cell Biol.* 8, 113–126.
- Gebauer, F., Hentze, M.W., 2004. Molecular mechanisms of translational control. *Nature reviews. Mol. Cell Biol.* 5, 827–835.
- Goebel, M., Yanagida, M., 1991. The TPR snap helix: a novel protein repeat motif from mitosis to transcription. *Trends Biochem. Sci.* 16, 173–177.
- Guo, J., Hui, D.J., Merrick, W.C., Sen, G.C., 2000a. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. *EMBO J.* 19, 6891–6899.
- Guo, J., Peters, K.L., Sen, G.C., 2000b. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. *Virology* 267, 209–219.
- Habjan, M., Hubel, P., Lacerda, B., Benda, C., Holze, C., Eberl, C.H., Mann, A., Kindler, E., Gil-Cruz, C., Ziebuhr, J., Thiel, V., Pichlmair, A., 2013. Sequestration by IFIT1 Impairs Translation of 2'-O-unmethylated Capped RNA. *PLoS Pathog.* 9, e1003663.
- Haline-Vaz, T., Silva, T.C., Zanchin, N.I., 2008. The human interferon-regulated ISG95 protein interacts with RNA polymerase II and shows methyltransferase activity. *Biochem. Biophys. Res. Commun.* 372, 719–724.
- Hefti, E., Bishop, D.H., Dubin, D.T., Stollar, V., 1975. 5' nucleotide sequence of sindbis viral RNA. *J. Virol.* 17, 149–159.
- Hercyk, N., Horikami, S.M., Moyer, S.A., 1988. The vesicular stomatitis virus L protein possesses the mRNA methyltransferase activities. *Virology* 163, 222–225.
- Hodel, A.E., Gershon, P.D., Quijcho, F.A., 1998. Structural basis for sequence-nonspecific recognition of 5'-capped mRNA by a cap-modifying enzyme. *Mol. Cell* 1, 443–447.
- Hodel, A.E., Gershon, P.D., Shi, X., Quijcho, F.A., 1996. The 1.85A structure of vaccinia protein VP39: a bifunctional enzyme that participates in the modification of both mRNA ends. *Cell* 85, 247–256.
- Honda, A., Mizumoto, K., Ishihama, A., 1999. Two separate sequences of PB2 subunit constitute the RNA cap-binding site of influenza virus RNA polymerase. *Genes Cells: Devoted Mol. Cell. Mech.* 4, 475–485.
- Hopkins, K.C., McLane, L.M., Magbool, T., Panda, D., Gordesky-Gold, B., Cherry, S., 2013. A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatching. *Genes Dev.* 27, 1511–1525.
- Hui, D.J., Bhasker, C.R., Merrick, W.C., Sen, G.C., 2003. Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP.Met-tRNAi. *J. Biol. Chem.* 278, 39477–39482.
- Hui, D.J., Terenzi, F., Merrick, W.C., Sen, G.C., 2005. Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation. *J. Biol. Chem.* 280, 3433–3440.
- Hyde, J.L., Gardner, C.L., Kimura, T., White, J.P., Liu, G., Trobaugh, D.W., Huang, C., Tonelli, M., Paessler, S., Takeda, K., Klimstra, W.B., Amarasinghe, G.K., Diamond, M.S., 2014. A viral RNA structural element alters host recognition of nonself RNA. *Science* 343, 783–787.
- Jackson, R.J., Hellen, C.U., Pestova, T.V., 2010. The mechanism of eukaryotic translation initiation and principles of its regulation. *Nature reviews. Mol. Cell Biol.* 11, 113–127.
- Jin, H., Elliott, R.M., 1993. Characterization of Bunyamwera virus S RNA that is transcribed and replicated by the L protein expressed from recombinant vaccinia virus. *J. Virol.* 67, 1396–1404.
- Katibah, G.E., Lee, H.J., Huizar, J.P., Vogan, J.M., Alber, T., Collins, K., 2013. tRNA Binding, Structure, and Localization of the Human Interferon-Induced Protein IFIT5. *Mol. Cell.*
- Katibah, G.E., Qin, Y., Sidote, D.J., Yao, J., Lambowitz, A.M., Collins, K., 2014. Broad and adaptable RNA structure recognition by the human interferon-induced tetratricopeptide repeat protein IFIT5. *Proc. Natl. Acad. Sci. USA* 111, 12025–12030.
- Kawakami, K., Mizumoto, K., Ishihama, A., 1983. RNA polymerase of influenza virus. IV. Catalytic properties of the capped RNA endonuclease associated with the RNA polymerase. *Nucleic Acids Res.* 11, 3637–3649.
- Kimura, T., Katoh, H., Kayama, H., Saiga, H., Okuyama, M., Okamoto, T., Umemoto, E., Matsuura, Y., Yamamoto, M., Takeda, K., 2013. Ifit1 inhibits Japanese Encephalitis Virus replication through binding to 5' Capped 2'-O Unmethylated RNA. *J. Virol.* 87, 9997–10003.
- King, R.W., Peters, J.M., Tugendreich, S., Rolfe, M., Hieter, P., Kirschner, M.W., 1995. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. *Cell* 81, 279–288.
- Kinney, R.M., Chang, G.J., Tsuchiya, K.R., Sneider, J.M., Roehrig, J.T., Woodward, T.M., Trent, D.W., 1993. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. *J. Virol.* 67, 1269–1277.
- Kinney, R.M., Johnson, B.J., Welch, J.B., Tsuchiya, K.R., Trent, D.W., 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. *Virology* 170, 19–30.
- Kitamura, Y., Spleiss, O., Li, H., Taniguchi, T., Kimura, H., Nomura, Y., Gebicke-Haerter, P.J., 2001. Lipopolysaccharide-induced switch between retinoid receptor (RXR) alpha and glucocorticoid attenuated response gene (GARG)-16 messenger RNAs in cultured rat microglia. *J. Neurosci. Res.* 64, 553–563.
- Klimstra, W.B., Ryman, K.D., Bernard, K.A., Nguyen, K.B., Biron, C.A., Johnston, R.E., 1999. Infection of neonatal mice with sindbis virus results in a systemic inflammatory response syndrome. *J. Virol.* 73, 10387–10398.
- Kobiler, D., Rice, C.M., Brodie, C., Shahar, A., Dubuisson, J., Halevy, M., Lustig, S., 1999. A single nucleotide change in the 5' noncoding region of Sindbis virus confers neurovirulence in rats. *J. Virol.* 73, 10440–10446.
- Koonin, E.V., 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. *J. Gen. Virol.* 74, 733–740 (Pt 4).
- Kuge, H., Brownlee, G.G., Gershon, P.D., Richter, J.D., 1998. Cap ribose methylation of c-mos mRNA stimulates translation and oocyte maturation in *Xenopus laevis*. *Nucleic Acids Res.* 26, 3208–3214.
- Kuge, H., Richter, J.D., 1995. Cytoplasmic 3' poly(A) addition induces 5' cap ribose methylation: implications for translational control of maternal mRNA. *EMBO J.* 14, 6301–6310.
- Kuhn, R.J., Griffin, D.E., Zhang, H., Niesters, H.G., Strauss, J.H., 1992. Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA. *J. Virol.* 66, 7121–7127.
- Kumar, P., Sweeney, T.R., Skabkin, M.A., Skabkina, O.V., Hellen, C.U., Pestova, T.V., 2014. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5'-terminal regions of cap0-, cap1- and 5'ppp-mRNAs. *Nucleic Acids Res.* 42, 3228–3245.
- Lamb, J.R., Tugendreich, S., Hieter, P., 1995. Tetratricopeptide repeat interactions: to TPR or not to TPR? *Trends Biochem. Sci.* 20, 257–259.
- Langberg, S.R., Moss, B., 1981. Post-transcriptional modifications of mRNA. Purification and characterization of cap I and cap II RNA (nucleoside-2'-)-methyltransferases from HeLa cells. *J. Biol. Chem.* 256, 10054–10060.
- Lehmann, M., Pahlmann, M., Jerome, H., Busch, C., Lelke, M., Gunther, S., 2014. Role of the C terminus of Lassa virus L protein in viral mRNA synthesis. *J. Virol.* 88, 8713–8717.
- Li, M.L., Rao, P., Krug, R.M., 2001. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. *EMBO J.* 20, 2078–2086.
- Li, S.H., Dong, H., Li, X.F., Xie, X., Zhao, H., Deng, Y.Q., Wang, X.Y., Ye, Q., Zhu, S.Y., Wang, H.J., Zhang, B., Leng, Q.B., Zuest, R., Qin, E.D., Qin, C.F., Shi, P.Y., 2013. Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation. *J. Virol.* 87, 5812–5819.
- Liu, Y., Zhang, Y.B., Liu, T.K., Gui, J.F., 2013. Lineage-specific expansion of IFIT gene family: an insight into coevolution with IFN gene family. *PLoS One* 8, e66859.
- Logue, C.H., Sheahan, B.J., Atkins, G.J., 2008. The 5' untranslated region as a pathogenicity determinant of Semliki Forest virus in mice. *Virus Genes* 36, 313–321.
- Lukashevich, I.S., Djavani, M., Shapiro, K., Sanchez, A., Ravkov, E., Nichol, S.T., Salvato, M.S., 1997. The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250kDa protein with monospecific antiserum. *J. Gen. Virol.* 78, 547–551 (Pt 3).
- Luongo, C.L., Contreras, C.M., Faretta, D.L., Nibert, M.L., 1998. Binding site for S-adenosyl-L-methionine in a central region of mammalian reovirus lambda2 protein. Evidence for activities in mRNA cap methylation. *J. Biol. Chem.* 273, 23773–23780.
- Ma, Y., Wei, Y., Zhang, X., Zhang, Y., Cai, H., Zhu, Y., Shilo, K., Oglesbee, M., Krakowka, S., Whelan, S.P., Li, J., 2014. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo. *J. Virol.* 88, 2913–2926.
- Martin, J.L., McMillan, F.M., 2002. SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. *Curr. Opin. Struct. Biol.* 12, 783–793.
- Menachery, V.D., Yount Jr., B.L., Jossel, L., Gralinski, L.E., Scobey, T., Agnihothram, S., Katze, M.G., Baric, R.S., 2014. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-O-methyltransferase activity. *J. Virol.* 88, 4251–4264.
- Mir, M.A., Duran, W.A., Hjelle, B.L., Ye, C., Panganiban, A.T., 2008. Storage of cellular 5' mRNA caps in P bodies for viral cap-snatching. *Proc. Natl. Acad. Sci. USA* 105, 19294–19299.
- Mir, M.A., Sheema, S., Haseeb, A., Haque, A., 2010. Hantavirus nucleocapsid protein has distinct m7G cap- and RNA-binding sites. *J. Biol. Chem.* 285, 11357–11368.
- Morin, B., Coutard, B., Lelke, M., Ferron, F., Kerber, R., Jamal, S., Frangeul, A., Baronti, C., Charrel, R., de Lamballerie, X., Vonrhein, C., Lescar, J., Bricogne, G., Gunther, S., Canard, B., 2010. The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription. *PLoS Pathog.* 6, e1001038.
- Patterson, J.L., Holloway, B., Kolakofsky, D., 1984. La Crosse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. *J. Virol.* 52, 215–222.

- Pei, Y., Schwer, B., Shuman, S., 2003. Interactions between fission yeast Cdk9, its cyclin partner Pch1, and mRNA capping enzyme Pct1 suggest an elongation checkpoint for mRNA quality control. *J. Biol. Chem.* 278, 7180-7188.
- Pestova, T.V., Kolupaeva, V.G., Lomakin, I.B., Pilipenko, E.V., Shatsky, I.N., Agol, V.I., Hellen, C.U., 2001. Molecular mechanisms of translation initiation in eukaryotes. *Proc. Natl. Acad. Sci. USA* 98, 7029-7036.
- Petterson, R.F., Soderlund, H., Kaariainen, L., 1980. The nucleotide sequences of the 5'-terminal T1 oligonucleotides of Semliki-Forest-virus 42-S and 26-S RNAs are different. *Eur. J. Biochem./FEBS* 105, 435-443.
- Pichlmair, A., Lassnig, C., Eberle, C.A., Gorna, M.W., Baumann, C.L., Burkard, T.R., Burckstummer, T., Stefanovic, A., Krieger, S., Bennett, K.L., Rulicke, T., Weber, F., Colinge, J., Muller, M., Superti-Furga, G., 2011. IFT1 is an antiviral protein that recognizes 5'-triphosphate RNA. *Nat. Immunol.* 12, 624-630.
- Plotch, S.J., Bouloy, M., Krug, R.M., 1979. Transfer of 5'-terminal cap of globin mRNA to influenza viral complementary RNA during transcription *in vitro*. *Proc. Natl. Acad. Sci. USA* 76, 1618-1622.
- Plotch, S.J., Bouloy, M., Ulmanen, I., Krug, R.M., 1981. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. *Cell* 23, 847-858.
- Raju, R., Raju, L., Hacker, D., Garcin, D., Compans, R., Kolakofsky, D., 1990. Nontemplated bases at the 5' ends of Tacaribe virus mRNAs. *Virology* 174, 53-59.
- Ray, D., Shah, A., Tilgner, M., Guo, Y., Zhao, Y., Dong, H., Deas, T.S., Zhou, Y., Li, H., Shi, P.Y., 2006. West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. *J. Virol.* 80, 8362-8370.
- Reguera, J., Weber, F., Cusack, S., 2010. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription. *PLoS Pathog.* 6, e1001101.
- Reinisch, K.M., Nibert, M.L., Harrison, S.C., 2000. Structure of the reovirus core at 3.6A resolution. *Nat.* 404, 960-967.
- Schroeder, S.C., Schwer, B., Shuman, S., Bentley, D., 2000. Dynamic association of capping enzymes with transcribing RNA polymerase II. *Genes Dev.* 14, 2435-2440.
- Schubert, H.L., Blumenthal, R.M., Cheng, X., 2003. Many paths to methyltransfer: a chronicle of convergence. *Trends Biochem. Sci.* 28, 329-335.
- Sharma, S., tenOever, B.R., Grandvaux, N., Zhou, G.P., Lin, R., Hiscott, J., 2003. Triggering the interferon antiviral response through an IKK-related pathway. *Science* 300, 1148-1151.
- Shatkin, A.J., 1985. mRNA cap binding proteins: essential factors for initiating translation. *Cell* 40, 223-224.
- Shi, L., Summers, D.F., Peng, Q., Galarz, J.M., 1995. Influenza A virus RNA polymerase subunit PB2 is the endonuclease which cleaves host cell mRNA and functions only as the trimeric enzyme. *Virology* 208, 38-47.
- Shi, X., Bernhardt, T.G., Wang, S.M., Gershon, P.D., 1997. The surface region of the bifunctional vaccinia RNA modifying protein VP39 that interfaces with Poly (A) polymerase is remote from the RNA binding cleft used for its mRNA 5' cap methylation function. *J. Biol. Chem.* 272, 23292-23302.
- Smietanski, M., Werner, M., Purta, E., Kaminska, K.H., Stepinski, J., Darzynkiewicz, E., Nowotny, M., Bujnicki, J.M., 2014. Structural analysis of human 2'-O-ribose methyltransferases involved in mRNA cap structure formation. *Nat. Commun.* 5.
- Smith, J.B., Herschman, H.R., 1996. The glucocorticoid attenuated response genes GARG-16, GARG-39, and GARG-49/IRG2 encode inducible proteins containing multiple tetratricopeptide repeat domains. *Arch. Biochem. Biophys.* 330, 290-300.
- Szretter, K.J., Daniels, B.P., Cho, H., Gaine, M.D., Yokoyama, W.M., Gale Jr., M., Virgin, H.W., Klein, R.S., Sen, G.C., Diamond, M.S., 2012. 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction *in vivo*. *PLoS Pathog.* 8, e1002698.
- Terenzi, F., Pal, S., Sen, G.C., 2005. Induction and mode of action of the viral stress-inducible murine proteins, P56 and P54. *Virology* 340, 116-124.
- Terlecky, S.R., Nuttley, W.M., McCollum, D., Sock, E., Subramani, S., 1995. The *Pichia pastoris* peroxisomal protein PAS8p is the receptor for the C-terminal tripeptide peroxisomal targeting signal. *EMBO J.* 14, 3627-3634.
- Tzamaras, D., Struhl, K., 1995. Distinct TPR motifs of Cyc8 are involved in recruiting the Cyc8-Tup1 corepressor complex to differentially regulated promoters. *Genes Dev.* 9, 821-831.
- Varela, M., Diaz-Rosales, P., Pereiro, P., Forn-Cuni, G., Costa, M.M., Dios, S., Romero, A., Figueras, A., Novoa, B., 2014. Interferon-induced genes of the expanded IFT family show conserved antiviral activities in non-mammalian species. *PLoS One* 9, e100015.
- Venkatesan, S., Gershowitz, A., Moss, B., 1980. Purification and characterization of mRNA guanylyltransferase from HeLa cell nuclei. *J. Biol. Chem.* 255, 2829-2834.
- Venkatesan, S., Moss, B., 1980. Donor and acceptor specificities of HeLa cell mRNA guanylyltransferase. *J. Biol. Chem.* 255, 2835-2842.
- Vieth, S., Torda, A.E., Asper, M., Schmitz, H., Gunther, S., 2004. Sequence analysis of L RNA of Lassa virus. *Virology* 318, 153-168.
- Wang, C., Pflugheber, J., Sumpter Jr., R., Sodor, D.L., Hui, D., Sen, G.C., Gale Jr., M., 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. *J. Virol.* 77, 3898-3912.
- White, L.J., Wang, J.G., Davis, N.L., Johnston, R.E., 2001. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region. *J. Virol.* 75, 3706-3718.
- Yagi, Y., Mizumoto, K., Kaziro, Y., 1983. Association of an RNA 5'-triphosphatase activity with RNA guanylyltransferase partially purified from rat liver nuclei. *EMBO J.* 2, 611-615.
- Yamada-Okabe, T., Doi, R., Shimmi, O., Arisawa, M., Yamada-Okabe, H., 1998. Isolation and characterization of a human cDNA for mRNA 5'-capping enzyme. *Nucleic Acids Res.* 26, 1700-1706.
- Yang, Z., Liang, H., Zhou, Q., Li, Y., Chen, H., Ye, W., Chen, D., Fleming, J., Shu, H., Liu, Y., 2012. Crystal structure of ISG54 reveals a novel RNA binding structure and potential functional mechanisms. *Cell Res.*
- Yuan, P., Bartlam, M., Lou, Z., Chen, S., Zhou, J., He, X., Lv, Z., Ge, R., Li, X., Deng, T., Fodor, E., Rao, Z., Liu, Y., 2009. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. *Nature* 458, 909-913.
- Zhang, Y., Wei, Y., Zhang, X., Cai, H., Niewiesk, S., Li, J., 2014. Rational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral mRNA cap methyltransferase. *J. Virol.* 88, 11411-11429.
- Zust, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B.W., Ziebuhr, J., Szretter, K.J., Baker, S.C., Barchet, W., Diamond, M.S., Siddell, S.G., Ludewig, B., Thiel, V., 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. *Nat. Immunol.* 12, 137-143.
- Zust, R., Dong, H., Li, X.F., Chang, D.C., Zhang, B., Balakrishnan, T., Toh, Y.X., Jiang, T., Li, S.H., Deng, Y.Q., Ellis, B.R., Ellis, E.M., Poidinger, M., Zolezzi, F., Qin, C.F., Shi, P.Y., Fink, K., 2013. Rational design of a live attenuated dengue vaccine: 2'-O-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. *PLoS Pathog.* 9, e1003521.